• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16733 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Health Technology Wales (HTW) Video feedback interventions to improve communication within family relationships and support children at risk
2024     Health Technology Wales (HTW) Low energy contact x-ray brachytherapy (CXB) for the treatment of early stage rectal cancer
2024     Health Technology Wales (HTW) Digital tools for the monitoring and management of wounds
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     Swiss Federal Office of Public Health (FOPH) Intra-articular glucocorticoid injections for osteoarthritis of the hip or knee
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2024     Swiss Federal Office of Public Health (FOPH) CAR-T-cell therapies
2024     Swiss Federal Office of Public Health (FOPH) Tumor treating fields (TTFields) therapy for patients with glioblastoma multiforme
2024     Belgian Health Care Knowledge Centre (KCE) Diagnostic Immunohistochemistry and electron microscopy testing in Belgium
2024     Belgian Health Care Knowledge Centre (KCE) Lung cancer screening in a high-risk population
2024     Belgian Health Care Knowledge Centre (KCE) The use of endothelial cell count in the preoperative evaluation of cataract surgery
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide clopidogrel use after an ischaemic stroke or transient ischaemic attack (TIA)
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection: a health technology assessment
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors: a health technology assessment
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain: a health technology assessment
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non–small cell lung cancer: a health technology assessment
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse: a health technology assessment
2024     Ontario Health Fractional exhaled nitric oxide testing for the diagnosis and management of asthma: a health technology assessment
2024     Ontario Health Sucrose octosulfate (SOS)-impregnated dressings for adults with difficult-to-heal noninfected diabetic foot ulcers and difficult-to-heal noninfected venous leg ulcers
2024     Ontario Health Level 2 polysomnography for the diagnosis of sleep disorders: a health technology assessment
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Ontario Health Minimally invasive bleb surgery for glaucoma: a health technology assessment
2024     Scottish Health Technologies Group (SHTG) Living Donor Transplantation - SHTG Assessment
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pharmacotherapy for transplant ineligible multiple myeloma
2024     NIHR Health Technology Assessment programme Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     NIHR Health Technology Assessment programme Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health Technology Assessment programme Cerclage suture type to prevent pregnancy loss in women requiring a vaginal cervical cerclage: the C-STICH RCT
2024     NIHR Health Technology Assessment programme Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     NIHR Health Technology Assessment programme Linkage of routinely collected NHS data to evaluate liaison mental health services: challenges and lessons learned
2024     NIHR Health Technology Assessment programme Infliximab versus alpha interferon in the treatment of Behçet’s disease: the BIO BEHÇET’S RCT
2024     NIHR Health Technology Assessment programme Development and evaluation of machine-learning methods in whole-body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer: the MALIBO diagnostic test accuracy study
2024     NIHR Health Technology Assessment programme Bezafibrate as treatment in males for Barth syndrome: CARDIOMAN, a double-blind, placebo-controlled crossover RCT
2024     NIHR Health Technology Assessment programme Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT
2024     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study
2024     NIHR Health Technology Assessment programme Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024     NIHR Health Technology Assessment programme Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2023     Malaysian Health Technology Assessment (MaHTAS) Ultra-portable digital x-ray system for TB screening
2023     Malaysian Health Technology Assessment (MaHTAS) Digital goniometer
2023     Malaysian Health Technology Assessment (MaHTAS) Far infrared therapy for arteriovenous fistulas and wound healing
2023     Institute of Health Economics (IHE) The impact of extreme heat events on health and health systems in Alberta: adaptation and mitigation strategies
2023     Institute of Health Economics (IHE) Optimizing MRI service capacity: review of the relationship between MRI delay and outcomes
2023     National Institute for Health and Care Excellence (NICE) Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. NICE highly specialised technologies guidance 22
2023     National Institute for Health and Care Excellence (NICE) Asfotase alfa for treating paediatric-onset hypophosphatasia. NICE highly specialised technologies guidance 23
2023     National Institute for Health and Care Excellence (NICE) Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy. NICE highly specialised technologies guidance 24
2023     National Institute for Health and Care Excellence (NICE) Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency. NICE highly specialised technologies guidance 26
2023     National Institute for Health and Care Excellence (NICE) Lumasiran for treating primary hyperoxaluria type 1. NICE highly specialised technologies guidance 25
2023     National Institute for Health and Care Excellence (NICE) Afamelanotide for treating erythropoietic protoporphyria. NICE highly specialised technologies guidance 27
2023     National Institute for Health and Care Excellence (NICE) Birch bark extract for treating epidermolysis bullosa. NICE highly specialised technologies guidance 28
2023     National Institute for Health and Care Excellence (NICE) Velmanase alfa for treating alpha-mannosidosis. NICE highly specialised technologies guidance 29
2023     Institute for Clinical and Economic Review (ICER) Atidarsagene autotemcel for metachromatic leukodystrophy
2023     Institute for Clinical and Economic Review (ICER) Gene therapies for sickle cell disease
2023     Institute for Clinical and Economic Review (ICER) Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023     Institute for Clinical and Economic Review (ICER) Lecanemab for early Alzheimer’s disease
2023     Institute for Clinical and Economic Review (ICER) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023     Norwegian Institute of Public Health (NIPH) Stockholm3 test to estimate the risk of prostate cancer: a single technology assessment
2023     Norwegian Institute of Public Health (NIPH) Transcutaneous non-invasive vagus nerve stimulation (gammaCore) for the treatment of cluster headache: A single technology assessment
2023     Health Information and Quality Authority (HIQA) Review of national public health strategies in selected countries
2023     WorkSafeBC Cryoneurolysis for shoulder pain
2023     National Institute for Health and Care Excellence (NICE) MRI-based technologies for assessing non-alcoholic fatty liver disease. NICE diagnostics guidance 50
2023     National Institute for Health and Care Excellence (NICE) MRI fusion biopsy systems for diagnosing prostate cancer. NICE diagnostics guidance 53
2023     National Institute for Health and Care Excellence (NICE) Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers. NICE diagnostics guidance 52
2023     National Institute for Health and Care Excellence (NICE) Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2023     National Institute for Health and Care Excellence (NICE) FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. NICE diagnostics guidance 48
2023     National Institute for Health and Care Excellence (NICE) AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023     National Institute for Health and Care Excellence (NICE) Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023     National Institute for Health and Care Excellence (NICE) Devices for remote monitoring of Parkinson's disease. NICE diagnostics guidance 51
2023     National Institute for Health and Care Excellence (NICE) AposHealth for knee osteoarthritis. NICE medical technologies guidance 76
2023     Penn Medicine Center for Evidence-based Practice (CEP) Mortality review 2023 update
2023     National Institute for Health and Care Excellence (NICE) Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. NICE interventional procedures guidance 747
2023     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical stimulation of the trigeminal nerve for ADHD. NICE interventional procedures guidance 748
2023     National Institute for Health and Care Excellence (NICE) Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. NICE interventional procedures guidance 749
2023     National Institute for Health and Care Excellence (NICE) Trabeculectomy with a biodegradable collagen matrix implant for glaucoma. NICE interventional procedures guidance 750
2023     National Institute for Health and Care Excellence (NICE) Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. NICE interventional procedures guidance 752
2023     National Institute for Health and Care Excellence (NICE) Transvenous obliteration for gastric varices. NICE interventional procedures guidance 751
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transluminal renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 754
2023     National Institute for Health and Care Excellence (NICE) Endoluminal gastroplication for gastro-oesophageal reflux disease. NICE interventional procedures guidance 753
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation for palliation of painful spinal metastases. NICE interventional procedures guidance 758
2023     National Institute for Health and Care Excellence (NICE) Maximal cytoreductive surgery for advanced ovarian cancer. NICE interventional procedures guidance 757
2023     National Institute for Health and Care Excellence (NICE) Focal therapy using high-intensity focused ultrasound for localised prostate cancer. NICE interventional procedures guidance 756
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thoracic duct embolisation for persistent chyle leak. NICE interventional procedures guidance 755
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. NICE interventional procedures guidance 759
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided biliary drainage for biliary obstruction. NICE interventional procedures guidance 761
2023     National Institute for Health and Care Excellence (NICE) Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea. NICE interventional procedures guidance 760
2023     National Institute for Health and Care Excellence (NICE) Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. NICE interventional procedures guidance 762
2023     National Institute for Health and Care Excellence (NICE) Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer. NICE interventional procedures guidance 763
2023     National Institute for Health and Care Excellence (NICE) Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. NICE interventional procedures guidance 765
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. NICE interventional procedures guidance 764
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2023     National Institute for Health and Care Excellence (NICE) Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 766